Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis
G. Androdias, Louise Noroy, Dimitri Psimaras, Cristina Birzu, Jean Pelletier, Ysoline Beigneux, Pierre Branger, Jonathan Ciron, Yannick Dananchet, Raphaël Depaz, Caroline Tilikete, Laurence Gignoux, Clara Grosset-Janin, Bastien Joubert, Philippe Kerschen, Arnaud Kwiatkowski, Christine Lebrun‐Frénay, Élisabeth Maillart, Aurélien Maureille, Philippe Nicolas, Thomas Le Roux, Romain Marignier, Sandra Vukusic, as the ICI-SEP group, under the aegis of the Société Francophone de la Sclérose en Plaques (SFSEP)
Abstract
OBJECTIVES: Immune checkpoint inhibitors (ICIs) are increasingly used in cancer treatment. Their mechanism of action raises the question of possible exacerbation of preexisting multiple sclerosis (MS). The aim of our study was to assess the risk of increased MS activity, defined by the occurrence of a relapse and/or a new MRI lesion, after ICI initiation. METHODS: This French multicentric study collected retrospective and prospective data on patients with MS treated with ICIs after a cancer diagnosis. RESULTS: We identified 18 patients with a median age of 48 years. Three of them (17%), all aged 50 years or younger, with a relapsing-remitting course, showed clinical and/or radiologic signs of MS activity 3 to 6 months after ICI initiation. They had stopped disease-modifying treatment (DMT) several months earlier, at the time of cancer diagnosis. Only one had both clinical and MRI activity, with mild severity and complete recovery. DISCUSSION: Our study suggests that the overall risk of MS activity under ICI is low and could be mainly driven by DMT discontinuation, as in MS in general. Although larger studies are needed for better risk assessment in younger patients with more active disease, ICI should be considered when needed in patients with MS.